...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Microbiology >Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow-Up of Cervical Intraepithelial Neoplasia
【24h】

Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow-Up of Cervical Intraepithelial Neoplasia

机译：Hybrid Capture II测试与基于PCR的人乳头瘤病毒检测方法在宫颈上皮内瘤变的诊断和治疗后随访之间的比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human papillomavirus (HPV) infection is the major cause of cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN), and HPV testing has therefore been proposed for improved triaging and follow-up of women treated for CIN. We compared two common HPV DNA detection tests (Hybrid Capture II [HCII] and PCR-enzyme immunosorbent assay (EIA) using the primers GP5+/GP6+ followed by HPV typing with reverse dot blot hybridization) for sensitivity and specificity for detection of CIN and of CIN recurrence after treatment. Two hundred and thirty-nine women referred to the Department of Obstetrics and Gynaecology in V?ster?s, Sweden, were enrolled because of atypical Pap smears; 177 of these were later treated for dysplasia by conization or loop diathermy. Samples for HPV DNA testing were taken before and 4 to 6 months after treatment. There was substantial agreement between the HCII and PCR-EIA (kappa, 0.70 before treatment and 0.72 after treatment). The sensitivity for histopathologically confirmed CIN III was 100.0% for PCR-EIA and 95.6% for HCII. For patients with CIN II or worse (CIN II+), the sensitivities were 92.9% (PCR-EIA) and 91.8% (HCII). The specificities for CIN II+ in the pretreatment setting were 30.4% for PCR-EIA and 24.1% for HCII. After treatment, the sensitivities for CIN III in cytology were 100.0% by both methods, and for CIN II+, sensitivities were 80.0% by both methods. The specificities for CIN II+ in the posttreatment setting were 83.5% for PCR and 85.4% for HCII. In conclusion, the sensitivities of both PCR-EIA and HCII are high and almost equal, suggesting that both methods are suitable as tools for detection and posttreatment follow-up of CIN II-III.
机译：人乳头瘤病毒（HPV）感染是子宫颈癌及其前体子宫颈上皮内瘤样变（CIN）的主要原因，因此提出了HPV检测以改善接受CIN治疗的妇女的分诊和随访情况。我们比较了两种常见的HPV DNA检测测试（Hybrid Capture II [HCII]和PCR酶免疫吸附测定（EIA），使用引物GP5 + / GP6 +，然后进行反向点印迹杂交的HPV分型）对CIN和治疗后CIN复发。由于非典型的子宫颈抹片检查，招募了瑞典维斯特市妇产科的239名妇女;其中有177例后来通过锥切或循环透热疗法治疗了不典型增生。在治疗前和治疗后4至6个月采集HPV DNA测试样品。 HCII和PCR-EIA之间存在实质性一致性（kappa，治疗前为0.70，治疗后为0.72）。经组织病理学确认的CIN III对PCR-EIA的敏感性为100.0％，对HCII为95.6％。对于CIN II或更严重（CIN II +）的患者，敏感性分别为92.9％（PCR-EIA）和91.8％（HCII）。在预处理环境中，CIN II +的特异性为PCR-EIA为30.4％，HCII为24.1％。治疗后，两种方法对细胞学CIN III的敏感性均为100.0％，对CIN II +两种方法的敏感性均为80.0％。在后处理环境中，CIN II +的特异性为PCR的83.5％和HCII的85.4％。总之，PCR-EIA和HCII的敏感性很高，几乎相等，表明这两种方法都适合作为CIN II-III的检测和后处理随访的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号